Investigational Drug for Adults with Advanced Solid Tumors
- Trial ID:
- IRB-21-7831
- Michael P. Kosty, M.D.
Eligible patients will be randomly assigned to take BBP-398 350mg or 450mg by mouth daily. You will know which BBP-398 dose level you have been assigned to.
Inclusion Criteria
*Have a diagnosis of advanced solid tumor with documented MAPK-pathway alteration (KRAS, BRAF Class II/Class III, or NF1 LOF) or diagnosis of Chordoma Cancer.*Have measureable disease confirmed by Computerized Tomograpy scan (CT) or Magnetic Resonance Imaging (MRI).
*Be capable of independently managing all self-care and be ambulatory and up and about at least 50% of each day (normal waking hours).
*Be able to swallow oral medication (capsules) without chewing, crushing, or opening.
*Be willing to record daily intake of study drug on a paper diary.
Contact Info:
- Clinical Research Services
- CRSLeadership@scrippshealth.org